CD19 and diffuse large B-cell lymphoma: Loncastuximab tesirine is a PBD-based ADC targeting CD19 refractory diffuse large B cell lymphoma (DLBCL) that has received its first FDA approval, demonstrating the potential for PBD-conjugated ADCs52.